Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Cadence Pharmaceuticals in a research note to investors on Tuesday, March 13rd.
Cadence Pharmaceuticals traded up 2.33% on Friday, hitting $3.07. Cadence Pharmaceuticals has a 52-week low of $3.25 and a 52-week high of $10.00. The company’s market cap is $262.5 million.
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates for use in the hospital setting.